Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory study to evaluate biomarkers of prospective multicenter observational study of atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer :J-TAIL

Next Previous
Trial Profile

An exploratory study to evaluate biomarkers of prospective multicenter observational study of atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer :J-TAIL

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms J-TAIL
  • Sponsors Chugai Pharmaceutical

Most Recent Events

  • 11 Aug 2021 Planned End Date changed from 22 Apr 2021 to 16 Apr 2021.
  • 05 Nov 2019 Planned End Date changed from 31 May 2021 to 22 Apr 2021.
  • 29 Oct 2019 Planned End Date changed from 30 Jun 2022 to 31 May 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top